MediWound Analyst Ratings
MediWound Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 187.29% | HC Wainwright & Co. | $23 → $26 | Maintains | Buy |
| 08/17/2023 | 297.79% | Oppenheimer | $63 → $36 | Maintains | Outperform |
| 08/17/2023 | 154.14% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/31/2023 | 596.13% | Oppenheimer | → $63 | Reiterates | Outperform → Outperform |
| 05/31/2023 | 154.14% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 03/17/2023 | 154.14% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 01/04/2023 | 154.14% | HC Wainwright & Co. | $5.5 → $23 | Maintains | Buy |
| 12/30/2022 | 176.24% | Cowen & Co. | $6 → $25 | Maintains | Outperform |
| 12/22/2022 | 176.24% | Maxim Group | → $25 | Initiates Coverage On | → Buy |
| 12/21/2022 | 596.13% | Oppenheimer | $9 → $63 | Maintains | Outperform |
| 11/16/2022 | -39.23% | HC Wainwright & Co. | $6 → $5.5 | Maintains | Buy |
| 07/18/2022 | -22.65% | Oppenheimer | → $7 | Assumes | → Outperform |
| 05/18/2022 | -11.6% | Wells Fargo | $7 → $8 | Maintains | Overweight |
| 03/21/2022 | -22.65% | Aegis Capital | $9 → $7 | Maintains | Buy |
| 08/17/2021 | -0.55% | Aegis Capital | $10 → $9 | Maintains | Buy |
| 08/11/2021 | -28.18% | HC Wainwright & Co. | $7 → $6.5 | Maintains | Buy |
| 03/02/2021 | 10.5% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 09/23/2020 | -33.7% | BTIG | → $6 | Initiates Coverage On | → Buy |
| 08/05/2019 | -39.23% | HC Wainwright & Co. | → $5.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年09月21日 | 187.29% | HC Wainwright公司 | $23→$26 | 维护 | 买 |
| 2023年08月17日 | 297.79% | 奥本海默 | $63→$36 | 维护 | 跑赢大盘 |
| 2023年08月17日 | 154.14% | HC Wainwright公司 | →$23 | 重申 | 购买→购买 |
| 2023年05月31日 | 596.13% | 奥本海默 | →$63 | 重申 | 跑赢→跑赢大盘 |
| 2023年05月31日 | 154.14% | HC Wainwright公司 | →$23 | 重申 | 购买→购买 |
| 03/17/2023 | 154.14% | HC Wainwright公司 | →$23 | 重申 | →购买 |
| 01/04/2023 | 154.14% | HC Wainwright公司 | $5.5→$23 | 维护 | 买 |
| 2022年12月30日 | 176.24% | 考恩公司 | $6→$25 | 维护 | 跑赢大盘 |
| 2022年12月22日 | 176.24% | Maxim集团 | →$25 | 开始承保 | →购买 |
| 2022年12月21日 | 596.13% | 奥本海默 | $9→$63 | 维护 | 跑赢大盘 |
| 2022年11月16日 | -39.23% | HC Wainwright公司 | $6→$5.5 | 维护 | 买 |
| 07/18/2022 | -22.65% | 奥本海默 | →$7 | 假设 | →跑赢大盘 |
| 2022/05/18 | -11.6% | 富国银行 | $7→$8 | 维护 | 超重 |
| 03/21/2022 | -22.65% | 宙斯盾资本 | $9→$7 | 维护 | 买 |
| 2021/08/17 | -0.55% | 宙斯盾资本 | $10→$9 | 维护 | 买 |
| 2021/08/11 | -28.18% | HC Wainwright公司 | $7→$6.5 | 维护 | 买 |
| 03/02/2021 | 10.5% | 宙斯盾资本 | →$10 | 开始承保 | →购买 |
| 09/23/2020 | -33.7% | BTIG | →$6 | 开始承保 | →购买 |
| 2019年08月05日 | -39.23% | HC Wainwright公司 | →$5.5 | 开始承保 | →购买 |
What is the target price for MediWound (MDWD)?
MediWound的目标价是多少？
The latest price target for MediWound (NASDAQ: MDWD) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $26.00 expecting MDWD to rise to within 12 months (a possible 187.29% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年9月21日报道了MediWound(纳斯达克代码：MDWD)的最新目标价。这家分析公司将目标价定为26美元，预计MDDD将在12个月内上涨至(可能上涨187.29%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for MediWound (MDWD)?
分析师对MediWound的最新评级是多少？
The latest analyst rating for MediWound (NASDAQ: MDWD) was provided by HC Wainwright & Co., and MediWound maintained their buy rating.
对MediWound(纳斯达克代码：MDWD)的最新分析师评级由HC Wainwright&Co.提供，MediWound维持买入评级。
When is the next analyst rating going to be posted or updated for MediWound (MDWD)?
MediWound(MDWD)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MediWound, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MediWound was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与MediWound的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。MediWound的上一次评级是在2023年9月21日提交的，因此您应该预计下一次评级将在2024年9月21日左右提供。
Is the Analyst Rating MediWound (MDWD) correct?
分析师对MediWound的评级正确吗？
While ratings are subjective and will change, the latest MediWound (MDWD) rating was a maintained with a price target of $23.00 to $26.00. The current price MediWound (MDWD) is trading at is $9.05, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的MediWound(MDWD)评级维持不变，目标价在23.00美元至26.00美元之间。MediWound目前的交易价格为9.05美元，超出了分析师的预测区间。